Dutch Cancer Society   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Amsterdam Netherlands (1949)

Organization Overview

First Clinical Trial
1999
NCT00243594
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Dutch Cancer Society

Active Ingredients

Drugs in Phase 4 Trials (1)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (1 trial)

Drugs in Phase 3 Trials (18)

bevacizumab (avastin) (3 trials)

carbon dioxide (dry ice) (1 trial)

celecoxib (celebrex) (1 trial)

cyclophosphamide (cytoxan) (3 trials)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (1 trial)

durvalumab (imfinzi) (1 trial)

fluorouracil (efudex) (2 trials)

irinotecan (Camptosar) (2 trials)

leucovorin (2 trials)

medroxyprogesterone (provera) (1 trial)

megestrol (megace) (1 trial)

nicotinamide (1 trial)

olaparib (lynparza) (1 trial)

oxaliplatin (eloxatin) (2 trials)

oxygen (1 trial)

ursodeoxycholic acid (1 trial)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 2 Trials (30)

177lu-psma-r2 (1 trial)

aldesleukin (Proleukin) (1 trial)

anakinra (Kineret) (1 trial)

bifidobacterium breve (1 trial)

bifidobacterium infantis (1 trial)

bifidobacterium longum (1 trial)

cetuximab (erbitux) (1 trial)

cisplatin (platinol) (1 trial)

daclizumab (Zenapax) (1 trial)

dendritic cells (1 trial)

everolimus (zortress) (1 trial)

inulin (1 trial)

isa 101 (1 trial)

labetuzumab govitecan (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus casei (1 trial)

lactobacillus delbrueckii (1 trial)

lactobacillus plantarum (1 trial)

mc2 tcr T cells (1 trial)

melanoma peptide-pulsed dendritic cells (1 trial)

miha-loaded pd-l-silenced dc vaccination (1 trial)

p53-slp (1 trial)

pacritinib (Vonjo) (1 trial)

streptococcus salivarius (1 trial)

sulindac (clinoril) (1 trial)

tumor-pulsed dendritic cells (1 trial)

ucb-nk cells (1 trial)

veliparib (1 trial)

vsl #3 (1 trial)

vvax001 (2 trials)

Drugs in Phase 1 Trials (3)

agen2034 (1 trial)

bevacizumab-irdye800cw (1 trial)

hespecta (1 trial)

Drugs in Other Trials (10)

acetylcholine chloride (miochol) (1 trial)

fesoterodine (toviaz) (1 trial)

fludeoxyglucose f-18 (1 trial)

gadobutrol (gadavist) (1 trial)

gemcitabine (gemzar) (1 trial)

girentuximab (1 trial)

hx4 (1 trial)

indium in-111 (1 trial)

nitroprusside (nipride) (1 trial)

sorafenib (nexavar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Adenoma (Phase 3)

Adenomatous Polyposis Coli (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Adenoid Cystic (Phase 2)

Carcinoma, Ductal (Phase 2)

Carcinoma, Ductal, Breast (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Colorectal Neoplasms (Phase 3)

Duodenal Neoplasms (Phase 3)

Fever (Phase 1)

Gastrointestinal Neoplasms (Phase 2)

Laryngeal Diseases (Phase 3)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Mucositis (Phase 2)

Multiple Myeloma (Phase 2)

Nasopharyngeal Neoplasms (Phase 3)

Neoplasms (Phase 3)

Neoplasms, Plasma Cell (Phase 2)

Neoplastic Cells, Circulating (Phase 2)

Neutropenia (Phase 2)

Ovarian Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 2)

Precancerous Conditions (Phase 1)

Primary Myelofibrosis (Phase 2)

Rectal Neoplasms (Phase 1)

Salivary Gland Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 36
  • # of Trial APIs: 62